Abstract: The present invention relates to a composition comprising levamlodipine besylate hydrate and its production, pharmaceutical preparations and use, especially the composition of (S)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-3,5-pyridinedicarboxylic acid-3-ethyl ester, 5-methyl ester benzenesulfonic acid hydrate and its production method and use. The composition of levamlodipine besylate crystallized in pure water and dried is easy for industrial production, has no organic solvent residue, good thermal stability and good dissolution amount in solid-form preparations.
Abstract: An antihypertensive pharmaceutical composition is provided, which contains levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide. In the present invention, levamlodipine and indapamide are administrated in combination for treating hypertension, a good synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone are mitigated.
Type:
Grant
Filed:
June 17, 2010
Date of Patent:
June 25, 2013
Assignee:
Shihuida Pharmaceuticals Group (JILIN) Ltd.
Inventors:
Yan ling Yang, Chuan xiao Xue, Xi tian Zhang, Huan Li, Sen tao Song
Abstract: A levamlodipine compound pharmaceutical composition is provided, which contains levamlodipine or a pharmaceutically acceptable salt thereof, and chlorthalidone. In the present invention, levamlodipine and chlorthalidone are administrated in combination for treating hypertension, a high synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone is mitigated. In addition, levamlodipine increases insulin sensitivity of an organism, and resists the side effect of increase in blood glucose level caused by chlorthalidone. The pharmaceutical composition of levamlodipine and chlorthalidone overcomes the disadvantage that levamlodipine takes effects slowly in hypertension repression.
Type:
Application
Filed:
June 17, 2010
Publication date:
February 16, 2012
Applicant:
SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD
Inventors:
Yan ling Yang, Chuan xiao Xue, Xi tian Zhang, Wei Xu, Yan Zhang
Abstract: A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a ? receptor blocking agent, and a use thereof are provided. An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically acceptable salt thereof, and a ? receptor blocking agent, in which the ? receptor blocking agent is one selected from nebivolol, bisoprolol, betaxolol, celiprolol, and nadolol. A use of the pharmaceutical composition in preparation of a medicine for treating hypertension is further provided. The pharmaceutical composition of the prevent invention has the advantages that the therapeutic effect is obvious, and the administration is convenient.
Type:
Application
Filed:
June 22, 2010
Publication date:
December 22, 2011
Applicant:
SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD
Inventors:
Yan Ling Yang, Chuan Xiao Zhang, Huan Li, Sen tao Song
Abstract: An antihypertensive pharmaceutical composition is provided, which contains levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide. In the present invention, levamlodipine and indapamide are administrated in combination for treating hypertension, a good synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone are mitigated.
Type:
Application
Filed:
June 17, 2010
Publication date:
October 27, 2011
Applicant:
SHIHUIDA PHARMACEUTICALS GROUP (JILIN) LTD
Inventors:
Yan Ling Yang, Chuan Xiao Xue, Xi Tian Zhang, Huan Li, Sen Tao Song